Previous 10 | Next 10 |
Invitae Corporation (NVTA) Q3 2021 Results Conference Call November 9, 2021 04:30 PM ET Company Participants Sean George – Chief Executive Officer Roxi Wen – Chief Financial Officer Vishal Sikri – President of NVTA Oncology Rakesh Patel – Chief Medical Officer Digi...
Invitae (NYSE:NVTA) shares have dropped 12% in after-hours trading after the company adjusted its full-year revenue outlook to a range below Street consensus. Invitae now expects 2021 revenue of $450M-$475M. Consensus is $484M. Revenue in Q3 2021 increased ~66% to $114.4M ...
Invitae (NYSE:NVTA): Q3 Non-GAAP EPS of -$0.81 beats by $0.01; GAAP EPS of -$0.91 misses by $0.09. Revenue of $114.4M (+66.4% Y/Y) misses by $12.16M. Billable volume of 296,000 in the quarter, approximately 89% increase compared to 157,000 in the same period in 2020. Shares -5%. The company h...
Invitae Reports $114.4 Million in Revenue Driven by 296,000 in Billable Volume in Third Quarter of 2021 -- Q3 2021 revenue increases more than 66% on volume growth of 89% from Q3 2020 -- -- Full-year 2021 revenue expected to grow 60-70%, or between $450-$475 million -- -...
Northwestern University and Invitae Present New Research Highlighting the Importance of Genetic Testing for Cardiovascular Conditions at the American Heart Association Scientific Sessions -- Data show benefits of multi-condition gene panels to identify and inform treatment of he...
Invitae (NYSE:NVTA) is scheduled to announce Q3 earnings results on Monday, November 8th, after market close. The consensus EPS Estimate is -$0.82 (-32.3% Y/Y) and the consensus Revenue Estimate is $126.56M (+84.1% Y/Y). In October, Seeking Alpha contributor Chris Lau opined that the pre...
Old West manages long only and long/short investment strategies based upon the companies that we uncover through our simple yet sound investment process. The third quarter of 2021 ended with the market searching for direction. The S&P 500 fell 4.6% in September but was still just ...
Invitae to Announce Third Quarter 2021 Financial Results on Monday, November 8, 2021 PR Newswire SAN FRANCISCO , Oct. 26, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third ...
After delivering enormous gains in 2020, the collection of exchange-traded funds or ETFs Cathie Wood manages for ARK Invest have underperformed this year. Is the internet's favorite stock market prognosticator losing her mojo? It's probably a little too early to know if 2020 was a o...
Invitae, UCL and the Francis Crick Institute Announce New Data From TRACERx Research Collaboration at the 2021 International Society of Liquid Biopsy Congress -- Study uses Invitae Personalized Cancer Monitoring (PCM™) liquid biopsy to accurately profile tumors and enhanc...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...